Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ASH 2024
Pharma
ASH: Lilly defends survival data blemish in novel BTK trial win
The overall survival analysis created a bit of a problem for Lilly as the hazard ratio edged above 1 in favor of control.
Angus Liu
Dec 9, 2024 5:45pm
ASH: Roche's subQ Lunsumio matches IV version in lymphoma
Dec 9, 2024 3:16pm
ASH: GSK details Blenrep's survival win against J&J's Darzalex
Dec 9, 2024 1:30pm
ASH: AstraZeneca proposes fixed-duration Calquence combos in CLL
Dec 8, 2024 11:00am
J&J angles Darzalex for first move into early-stage myeloma
Nov 8, 2024 9:53am
.jpg?VersionId=Y5_vD81yVN_ucSNA7GQvoAMDipDkVLCN)
